Detailed narrative
Strategic Expansion into Multi-Use Platform
Virtuix is evolving from a consumer gaming focus to a multi-use platform strategy, expanding into defense, enterprise, and healthcare. This quarter saw significant validation with partnerships including Meta for consumer products, the US Marine Corps for defense training, Tesla and NASA for enterprise applications, and Sirica Therapeutics for healthcare. This approach aims to leverage high-volume consumer sales with high-value defense and enterprise contracts, supported by recurring software licensing and custom simulation developments.
Consumer Business Momentum with Meta Partnership
The launch of OmniOne for Quest in collaboration with Meta in late June has significantly boosted consumer orders, which are up approximately 150% since the launch. This partnership provides OmniOne access to Meta's estimated 6 million active Quest users, materially expanding Virtuix's addressable market. The company is actively exploring joint marketing opportunities and product bundling with Meta to sustain this momentum, believing they have only scratched the surface of potential growth.
Growing Defense Footprint and M&A Strategy
Virtuix is expanding its defense business, serving as the lead systems integrator for an infantry fire team trainer for the US Marine Corps, with delivery expected in Q4 2026. The company also entered the counter-drone training market and has active engagements across all major US military branches. To accelerate growth, a board special committee is reviewing defense M&A targets with $10 million to $50 million in annual revenue, seeking companies with government contract vehicles, sales channels, and recurring defense revenue.
Enterprise and Healthcare Traction
The company secured its first OmniOne Enterprise System sale to Tesla for its Optimus humanoid robot division, and was selected by NASA for a year-long Moon and Mars mission simulation. In healthcare, Virtuix signed a strategic partnership with Sirica Therapeutics to use OmniOne in autism therapy for children, with plans for deployment in approximately 100 treatment centers nationwide. These enterprise and healthcare initiatives are expected to generate high-margin hardware revenue and recurring software licensing fees.
Financial Performance and Path to Profitability
Despite a 26% year-over-year decline in net sales to $767,000 due to timing of📎 legacy backlog fulfillment, gross profit increased 29% to $227,000, and gross margin expanded by 13 percentage points to 30%. Operating expenses rose 86% to $4.1 million, primarily due to public company costs. The company's priorities include accelerating consumer revenue growth, advancing defense programs, expanding enterprise sales, building out the healthcare vertical, and ultimately driving towards profitability by leveraging improved gross margins and high-value contracts.